Literature DB >> 16971888

Public health response to varicella outbreaks--United States, 2003-2004.

.   

Abstract

Since introduction of varicella vaccine in 1995, incidence of varicella has decreased as vaccination coverage has increased. Nevertheless, varicella outbreaks continue to occur, even among populations with high vaccination coverage. Although varicella typically is mild, the outbreaks can last for several months and be challenging and costly for health departments to control. In 2005, CDC conducted a national survey to determine the distribution and extent of reported varicella outbreaks during 2003-2004 and the public health response. This report summarizes the results of that survey, which indicated that varicella outbreaks are still common and that health jurisdictions are responding to these outbreaks, although they have varying definitions and guidelines for varicella-outbreak management.

Mesh:

Year:  2006        PMID: 16971888

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  4 in total

1.  Varicella zoster virus transmission in the vaccine era: unmasking the role of herpes zoster.

Authors:  Karen C Bloch; James G Johnson
Journal:  J Infect Dis       Date:  2012-03-27       Impact factor: 5.226

2.  Safety of a second dose of varicella vaccine administered at 4 to 6 years of age in healthy children in Argentina.

Authors:  Diego Fridman; Andrea Monti; Marie-Claude Bonnet; Judith Armoni; Daniel Stamboulian
Journal:  Hum Vaccin       Date:  2011-10-01

3.  Varicella Vaccination Two-Dose Recommendations: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).

Authors:  Ben Tan; Shainoor Ismail
Journal:  Can Commun Dis Rep       Date:  2010-09-20

Review 4.  Primary versus secondary failure after varicella vaccination: implications for interval between 2 doses.

Authors:  Paolo Bonanni; Anne Gershon; Michael Gershon; Andrea Kulcsár; Vassiliki Papaevangelou; Bernard Rentier; Catherine Sadzot-Delvaux; Vytautas Usonis; Timo Vesikari; Catherine Weil-Olivier; Peter de Winter; Peter Wutzler
Journal:  Pediatr Infect Dis J       Date:  2013-07       Impact factor: 2.129

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.